Sign In
Buy KYMR
$73.21
+1.92 (+2.69%)
At Close: Jun 03, 2026
Kymera Therapeutics Announces Proposed Public Offering
04:01pm, Monday, 08'th Dec 2025
WATERTOWN, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines
This Drugmaker's Stock Is Soaring Over 40% Monday
03:50pm, Monday, 08'th Dec 2025
Kymera Therapeutics (KYMR) shares surged over 40% to an all-time high Monday afternooon after the drugmaker reported positive results from an early test of an oral anti-inflammatory drug.
Kymera Therapeutics, Inc. (KYMR) Discusses KT-621 BroADen Phase 1b Results in Atopic Dermatitis Transcript
03:47pm, Monday, 08'th Dec 2025
Kymera Therapeutics, Inc. (KYMR) Discusses KT-621 BroADen Phase 1b Results in Atopic Dermatitis Transcript
Kymera Rockets, Pulling Nurix Higher. Does It Have The Next Dupixent?
09:27am, Monday, 08'th Dec 2025
Kymera Therapeutics could have the next Dupixent, analysts said Monday, as shares skyrocketed on promising test results in eczema.
Kymera's KT-621 Shines: Phase 1b Data Boosts Momentum
09:15am, Monday, 08'th Dec 2025
Kymera Therapeutics, Inc. reported robust Phase 1b results for KT-621, showing deep STAT6 degradation and strong clinical efficacy in atopic dermatitis. KT-621 demonstrated a favorable safety profile,
Kymera Therapeutics Stock Soars 30%. Why Investors Are Excited About Its Anti-Inflammatory Drug.
07:42am, Monday, 08'th Dec 2025
The biopharma company is counting on KT-621 to treat patients with Type 2 inflammatory diseases.
KT-621 achieved deep STAT6 degradation across both the 100 mg and 200 mg dose groups tested, with median reductions of 94% and 98% in skin and blood, respectively, demonstrating strong translation fro
Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025
04:01pm, Friday, 05'th Dec 2025
Company to host video conference call and webcast at 8:00 a.m. ET on Monday, December 8, 2025 WATERTOWN, Mass.
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
12:37pm, Thursday, 04'th Dec 2025
Kymera Therapeutics (KYMR) reported earnings 30 days ago. What's next for the stock?
Kymera Therapeutics, Inc. (KYMR) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
01:43pm, Wednesday, 03'rd Dec 2025
Kymera Therapeutics, Inc. (KYMR) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Kymera Trades Near 52-Week High: Time to Buy, Sell or Hold the Stock?
08:36am, Wednesday, 26'th Nov 2025
KYMR hits a 52-week high as optimism builds around KT-621's progress and upcoming data in atopic dermatitis.
Data from the KT-621 BROADEN2 Phase 2b AD patient trial expected to be reported by mid-2027 KT-621 BREADTH Phase 2b trial in asthma on track to initiate in 1Q26 Completed dosing in KT-621 BroADen Phas
Kymera Therapeutics to Participate in Upcoming December Investor Conferences
07:00am, Monday, 24'th Nov 2025
WATERTOWN, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicine
Kymera Therapeutics, Inc. (KYMR) Presents at UBS Global Healthcare Conference 2025 Transcript
03:31pm, Monday, 10'th Nov 2025
Kymera Therapeutics, Inc. ( KYMR ) UBS Global Healthcare Conference 2025 November 10, 2025 11:45 AM EST Company Participants Jared Gollob - Chief Medical Officer Conference Call Participants Xiaochuan
Kymera Therapeutics, Inc. (KYMR) Q3 2025 Earnings Call Transcript
04:26pm, Tuesday, 04'th Nov 2025
Kymera Therapeutics, Inc. ( KYMR ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants Justine Koenigsberg - Vice President of Investor Relations Nello Mainolfi - Co-Founder, Presi
